We present a pharmacogenetic study of acute antipsychotic (AP)-induced extrapyramidal symptoms (EPS) using an extensive linkage disequilibrium mapping approach in seven-candidate genes with a well-established link to dopamine (DRD2, DRD3, ACE, COMT, DAT, MAO-A, MAO-B). From a cohort of 321 psychiatric inpatients, 81 cases presenting with EPS (Simpson-Angus 3) and 189 controls presenting without EPS (Simpson-Angus ≥3) took part. Eighty-four-tag single nucleotide polymorphisms (SNPs) in candidate genes were genotyped. After extensive data cleaning, 70 SNPs were analyzed for association of single markers and haplotypes. AP dosage, AP-DRD2 blockade potency and age were identified as susceptibility factors for AP-induced EPS. One SNP of the DRD3 gene, rs167771, achieved significant association with EPS risk after Bonferroni correction (nominal P-value 1.3 × 10 &-4) in the patients treated with risperidone (132 patients). AP-induced EPS remains a serious public health problem. Our finding of a common SNP (rs167771) in the DRD3 gene provides a strong new candidate gene for risperidone-induced EPS.© 2009 Nature Publishing Group All rights reserved.
CITATION STYLE
Gassó, P., Mas, S., Bernardo, M., Lvarez, S., Parellada, E., & Lafuente, A. (2009). A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics Journal, 9(6), 404–410. https://doi.org/10.1038/tpj.2009.26
Mendeley helps you to discover research relevant for your work.